Powering cell stress detection with world-class innovative technologies
CalRexin™ platform technologies are engineered to deliver unparalleled first-in-class proprietary products including imaging reagents that are now available globally, to be followed by therapeutics and diagnostics.
Apop’s breakthrough CalRexin™ technologies are transforming our knowledge of complex cell stress mechanisms associated with programmed cell death (PCD), which is important for several significant diseases.
We have launched a pipeline of proprietary novel imaging reagents to interrogate these mechanisms, alongside developing a range of emerging therapeutics and diagnostics products. All Apop products are based on our proprietary calcitonin receptor antibody technology, CalRexin™, that targets a novel extracellular marker of these complex processes, is accumulated into live stressed cells and so far, is proven for detection of apoptosis and autophagy.
Apop’s CalRexin™:pHrodo™ Red, a highly selective marker of autophagy, is the latest addition to the CalRexin range of cell stress imaging reagents. They are first-in-class products that deliver high-fidelity data to meet a growing demand for more effective tools to detect and monitor cell stress that leads to autophagy and apoptosis. The dysregulation of these critical cellular pathways are associated with diseases such as neurodegeneration, cancer, cardiovascular diseases and pathogenic infections.
All Apop products are for Research Use Only (RUO). Not for diagnostic or therapeutic use.
what we do with CalRexin™
-
Research Reagents
Apop has launched CalRexin™:pHrodo™ Red, a first in class imaging reagent for real-time autophagy detection, enhancing our differentiated product offering to researchers and industry seeking better tools to detect and monitor cell stress processes. Apop’s proprietary antibody:fluorophore conjugates reveal novel pathways of autophagy programmed cell death in live cells and provide insights into these complex mechanisms previously unseen.
-
Develop Therapeutics
Apop is developing CalRexin™ into a powerful delivery vehicle for therapeutics (as antibody-toxin and antibody-drug conjugates) to treat refractory tumours.
-
Develop Imaging Agents
Apop is developing novel CalRexin™ conjugates as diagnostic tools for real time imaging of PCD in patients.
Latest News
Apop Biosciences announces new distributor
Apop is pleased to announce the appointment of Biozol Diagnostica Vertrieb GmbH as our German, Austrian and Swiss distrbutor.
Apop releases its powerful autophagy imaging reagent CalRexin™:pHrodo™ Red
CalRexin™:pHrodo™ Red is a first-in-class imaging reagent that identifies a novel marker of autophagy, namely activated calcitonin receptor.
CalRexin™:pHrodo™ Red resists photobleaching and is extremely stable, properties that are essential for high throughput/content imaging of live cells over 24 hours at multiple timepoints. Unlike alternatives, CalRexin™:pHrodo™ Red passes through sequential structures of the autophagy pathway from early endosomes to autolysosomes where it fluoresces brightly in the low pH environment, illuminating multiple components of the autophagic process, in real time.
CalRexin™:pHrodo™ Red provides exceptional, high-fidelity data and is utilised for primary screening of autophagy-modulating compounds from small molecule libraries on high throughput/content platforms, invaluable for drug discovery.
All Apop products are for Research Use Only (RUO). Not for diagnostic or therapeutic use. pHrodo™ is a registered trademark of Thermo Fisher Scientific.